OTCMKTS:DSRLF DiaSorin (DSRLF) Stock Price, News & Analysis $107.68 0.00 (0.00%) As of 06/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About DiaSorin Stock (OTCMKTS:DSRLF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DiaSorin alerts:Sign Up Key Stats Today's Range$107.68▼$107.6850-Day Range$104.69▼$112.3052-Week Range$100.01▼$112.30VolumeN/AAverage Volume106 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewDiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.Read More… Receive DSRLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaSorin and its competitors with MarketBeat's FREE daily newsletter. Email Address DSRLF Stock News HeadlinesDiaSorin: Anticipate A Double-Digit EBITDA Growth RateMay 2, 2025 | seekingalpha.comDiaSorin S.p.A. (0GZX) Receives a Hold from BarclaysMarch 25, 2025 | markets.businessinsider.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.July 1 at 2:00 AM | Timothy Sykes (Ad)DiaSorin S.p.A. (0GZX) Receives a Sell from Kepler CapitalMarch 19, 2025 | markets.businessinsider.comDiaSorin stock rises despite mixed financial resultsMarch 17, 2025 | in.investing.comDiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | seekingalpha.comItaly's DiaSorin ex-Covid revenue in line with guidanceMarch 14, 2025 | reuters.comUBS Remains a Hold on DiaSorin S.p.A. (0GZX)March 6, 2025 | markets.businessinsider.comSee More Headlines DSRLF Stock Analysis - Frequently Asked Questions How have DSRLF shares performed this year? DiaSorin's stock was trading at $106.8545 at the start of the year. Since then, DSRLF stock has increased by 0.8% and is now trading at $107.68. View the best growth stocks for 2025 here. How do I buy shares of DiaSorin? Shares of DSRLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/01/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED PRODUCTS Sub-IndustryMisc. Current SymbolOTCMKTS:DSRLF CIKN/A Webwww.diasoringroup.com Phone391614871FaxN/AEmployees3,186Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio2.26 Sales & Book Value Annual Sales$1.28 billion Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.02 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:DSRLF) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaSorin S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaSorin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.